Decreasing mitochondrial fission ameliorates HIF-1α-dependent pathological retinal angiogenesis
© 2024. The Author(s), under exclusive licence to Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Chinese Pharmacological Society..
Angiogenesis plays a critical role in many pathological processes, including irreversible blindness in eye diseases such as retinopathy of prematurity. Endothelial mitochondria are dynamic organelles that undergo constant fusion and fission and are critical signalling hubs that modulate angiogenesis by coordinating reactive oxygen species (ROS) production and calcium signalling and metabolism. In this study, we investigated the role of mitochondrial dynamics in pathological retinal angiogenesis. We showed that treatment with vascular endothelial growth factor (VEGF; 20 ng/ml) induced mitochondrial fission in HUVECs by promoting the phosphorylation of dynamin-related protein 1 (DRP1). DRP1 knockdown or pretreatment with the DRP1 inhibitor Mdivi-1 (5 μM) blocked VEGF-induced cell migration, proliferation, and tube formation in HUVECs. We demonstrated that VEGF treatment increased mitochondrial ROS production in HUVECs, which was necessary for HIF-1α-dependent glycolysis, as well as proliferation, migration, and tube formation, and the inhibition of mitochondrial fission prevented VEGF-induced mitochondrial ROS production. In an oxygen-induced retinopathy (OIR) mouse model, we found that active DRP1 was highly expressed in endothelial cells in neovascular tufts. The administration of Mdivi-1 (10 mg·kg-1·d-1, i.p.) for three days from postnatal day (P) 13 until P15 significantly alleviated pathological angiogenesis in the retina. Our results suggest that targeting mitochondrial fission may be a therapeutic strategy for proliferative retinopathies and other diseases that are dependent on pathological angiogenesis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Acta pharmacologica Sinica - (2024) vom: 02. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Huang, Shu-Qi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Dynamin-related protein 1 |
|---|
| Anmerkungen: |
Date Revised 02.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1038/s41401-024-01262-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370554035 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370554035 | ||
| 003 | DE-627 | ||
| 005 | 20240404000613.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240404s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41401-024-01262-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1363.xml |
| 035 | |a (DE-627)NLM370554035 | ||
| 035 | |a (NLM)38565961 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Huang, Shu-Qi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Decreasing mitochondrial fission ameliorates HIF-1α-dependent pathological retinal angiogenesis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 02.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024. The Author(s), under exclusive licence to Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Chinese Pharmacological Society. | ||
| 520 | |a Angiogenesis plays a critical role in many pathological processes, including irreversible blindness in eye diseases such as retinopathy of prematurity. Endothelial mitochondria are dynamic organelles that undergo constant fusion and fission and are critical signalling hubs that modulate angiogenesis by coordinating reactive oxygen species (ROS) production and calcium signalling and metabolism. In this study, we investigated the role of mitochondrial dynamics in pathological retinal angiogenesis. We showed that treatment with vascular endothelial growth factor (VEGF; 20 ng/ml) induced mitochondrial fission in HUVECs by promoting the phosphorylation of dynamin-related protein 1 (DRP1). DRP1 knockdown or pretreatment with the DRP1 inhibitor Mdivi-1 (5 μM) blocked VEGF-induced cell migration, proliferation, and tube formation in HUVECs. We demonstrated that VEGF treatment increased mitochondrial ROS production in HUVECs, which was necessary for HIF-1α-dependent glycolysis, as well as proliferation, migration, and tube formation, and the inhibition of mitochondrial fission prevented VEGF-induced mitochondrial ROS production. In an oxygen-induced retinopathy (OIR) mouse model, we found that active DRP1 was highly expressed in endothelial cells in neovascular tufts. The administration of Mdivi-1 (10 mg·kg-1·d-1, i.p.) for three days from postnatal day (P) 13 until P15 significantly alleviated pathological angiogenesis in the retina. Our results suggest that targeting mitochondrial fission may be a therapeutic strategy for proliferative retinopathies and other diseases that are dependent on pathological angiogenesis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Dynamin-related protein 1 | |
| 650 | 4 | |a Mdivi-1 | |
| 650 | 4 | |a ROS. | |
| 650 | 4 | |a glycolysis | |
| 650 | 4 | |a mitochondrial fission | |
| 650 | 4 | |a pathological angiogenesis | |
| 700 | 1 | |a Cao, Kai-Xiang |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Cai-Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Pei-Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yi-Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yu-Ting |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Shi-Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Bai, Zai-Xia |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Shuai |e verfasserin |4 aut | |
| 700 | 1 | |a Liao, Mu-Xi |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Qiao-Wen |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Guo-Qi |e verfasserin |4 aut | |
| 700 | 1 | |a He, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Yi-Ming |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta pharmacologica Sinica |d 2000 |g (2024) vom: 02. Apr. |w (DE-627)NLM111735181 |x 1745-7254 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:02 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41401-024-01262-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 02 |c 04 | ||